The COVID-19 pandemic has presented several operational challenges for the pharmaceutical and healthcare industry.
GlobalData had conducted a survey to identify how the COVID-19 pandemic affected clinical trial planning for clinical trial sponsors, collaborators or contract research organisations (CROs).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
An analysis of the survey reveals that 30% of the respondents believe that the pandemic would impact patient recruitment, while 17% of the companies felt that investigator recruitment would be affected.
Impact of COVID-19 Social Distancing Measures on Clinical Trials
Another 17% of the respondents highlighted that the pandemic will disrupt the supply of clinical trial materials due to restrictions and lockdowns measures.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFurthermore, 14% of the respondents are planning to either cancel or postpone trials, while another 10% opnied that regulator resources are stretched amid the pandemic.
Around 5% of the surveyed companies are mulling to change the location of the trial, while 4% noted that they have no clinical trials planned in the next two years.
Only 4% of the respondents said that the COVID-19 pandemic will not affect their trial programmes.
The analysis is based on responses received from the GlobalData Coronavirus Survey – Pharmaceutical Imports/Exports and Supply Chain, 2020 conducted between 13 March and 24 March 2020.
